Skip to main content
. 2021 Jan 25;2021:6664557. doi: 10.1155/2021/6664557

Table 2.

Phenotypes of resistance detected among the E. coli isolates recovered from pets.

Phenotype of resistance Number of isolates Percentage of isolates
CRO 1 2.17
STR 1 2.17
ATM 1 2.17
NALa 5 10.8
KAN + NAL 1 2.17
TET + STR 1 2.17
NAL + TETa 2 4.3
NAL + CRO 1 2.17
AMC + CFZ + AMP 1 2.17
SXT + CFZ + AMP 1 2.17
SXT + CIP + NAL + TETa 1 2.17
STX + NAL + TET + STRa 1 2.17
SXT + TET + STR + AMP + CROa 1 2.17
STX + TET + STR + AMP + CROa 1 2.17
NA + TET + STR + AMP + CROa 1 2.17
STX + CFZ + NAL + TET + AMPa 1 2.17
SXT + SAM + CIP + NAL + TET + AMPa 1 2.17
STX + SAM + CIP + NAL + TET + STR + AMPa 1 2.17
STX + SAM + NAL + TET + AMP + CRO + ATMa 1 2.17
CTX + CFZ + SAM + CPD + CRO + CIP + NAL + AMP + CROb 1 2.17
CAZ + CTX + AMC + CFZ + SAM + CIP + CRO + AMP + ATMb 1 2.17

a E. coli developed on the plate with ciprofloxacin; bE. coli developed on the plate with cefotaxime. TET, tetracycline; AMP, ampicillin; STR, streptomycin; STX, sulfamethoxazole-trimethoprim; CRO, ceftriaxone; CFZ, cefazolin; CPD, cefpodoxime; CAZ, ceftazidime; CTX, cefotaxime; ATM, aztreonam; NAL, nalidixic acid; CIP, ciprofloxacin; SAM, ampicillin-sulbactam; AMC, amoxicillin-clavulanic acid; GEN, gentamicin; KAN, kanamycin.